Ginkgo Bioworks Holdings, Inc. (DNA) 10-Year Financial Performance & Capital Metrics

DNA •

HealthcareBiotechnologyDrug Discovery and Antibody Platforms

AboutGinkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Show more

Revenue $170M -25.1%
EBITDA -$315M +36.5%
Net Income -$313M +42.8%
EPS (Diluted) -5.64 +46.5%
Gross Margin 81.48% -1.9%
EBITDA Margin -185.29% +15.3%
Operating Margin -185.29% +24.8%
Net Margin -183.81% +23.7%
ROE -51.08% +15.3%
ROIC -34.25% +58.6%
Debt/Equity 0.82 +25.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 17.3%
✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y17.29%

3Y-29.11%

TTM-25.06%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM42.83%

EPS CAGR

10Y-

5Y-

3Y-

TTM47.1%

ROCE

10Y Avg-56%

5Y Avg-71.87%

3Y Avg-37.53%

Latest-27.49%

Peer Comparison

Drug Discovery and Antibody Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
REGNRegeneron Pharmaceuticals, Inc.	107.56B	781.67	18.84	0.99%	31.41%	14.41%	3.79%	0.09
CTMXCytomX Therapeutics, Inc.	430.14M	5.37	14.13	36.45%	24.66%	26.09%
PRTCPureTech Health plc	405.3M	16.77	8.39	44.98%	-495.91%	-8.53%		0.05
DNAGinkgo Bioworks Holdings, Inc.	327.53M	6.75	-1.20	-25.06%	-183.81%	-61.5%		0.82
BCYCBicycle Therapeutics plc	111.38M	5.73	-1.98	30.76%	-8.85%	-40.53%		0.01
CCCCC4 Therapeutics, Inc.	261.67M	2.70	-2.13	-100%		-40.92%		0.23
MOLNMolecular Partners AG	187.84M	5.02	-2.43	-29.38%	-10.87%	-63.06%		0.02
RXRXRecursion Pharmaceuticals, Inc.	1.94B	3.67	-2.55	26.92%	-8.65%	-57.01%		0.07

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	54.18M	76.66M	313.84M	477.71M	251.46M	227.04M	170.16M
Revenue Growth %	-	41.48%	309.4%	52.21%	-47.36%	-9.71%	-25.06%
Cost of Goods Sold+	0	15.61M	129.69M	204.22M	54.01M	38.55M	31.52M
COGS % of Revenue	-	20.36%	41.32%	42.75%	21.48%	16.98%	18.52%
Gross Profit+	54.18M	61.05M	184.15M	273.49M	197.45M	188.49M	138.63M
Gross Margin %	100%	79.64%	58.68%	57.25%	78.52%	83.02%	81.48%
Gross Profit Growth %	-	12.66%	201.65%	48.52%	-27.8%	-4.54%	-26.45%
Operating Expenses+	125.78M	198.07M	2.01B	2.48B	1.06B	748.25M	453.91M
OpEx % of Revenue	232.14%	258.39%	641.29%	519.66%	422.28%	329.56%	266.76%
Selling, General & Admin	29.48M	38.31M	862.95M	1.43B	385.02M	246.16M	183.29M
SG&A % of Revenue	54.41%	49.97%	274.97%	299.31%	153.12%	108.42%	107.72%
Research & Development	96.3M	159.77M	1.15B	1.05B	580.62M	424.06M	243.77M
R&D % of Revenue	177.73%	208.42%	366.32%	220.35%	230.9%	186.78%	143.27%
Other Operating Expenses	0	0	0	0	96.21M	78.03M	26.85M
Operating Income+	-71.6M	-137.03M	-1.83B	-2.21B	-864.41M	-559.76M	-315.28M
Operating Margin %	-132.14%	-178.75%	-582.62%	-462.41%	-343.76%	-246.54%	-185.29%
Operating Income Growth %	-	-91.38%	-1234.38%	-20.81%	60.87%	35.24%	43.68%
EBITDA+	-60.84M	-123.16M	-1.8B	-2.15B	-792.85M	-496.74M	-315.28M
EBITDA Margin %	-112.29%	-160.67%	-573.35%	-449.51%	-315.31%	-218.79%	-185.29%
EBITDA Growth %	-	-102.43%	-1360.98%	-19.34%	63.08%	37.35%	36.53%
D&A (Non-Cash Add-back)	10.76M	13.86M	29.08M	61.63M	71.55M	63.02M	0
EBIT	-117.41M	-122.45M	-1.84B	-2.12B	-892.85M	-547.41M	0
Net Interest Income+	3.33M	197K	-1.54M	20.16M	57.12M	38.52M	0
Interest Income	5.76M	2.58M	837K	20.26M	57.22M	38.61M	22.62M
Interest Expense	2.42M	2.38M	2.37M	106K	93K	94K	0
Other Income/Expense	-48.24M	12.19M	-9.65M	87.55M	-28.53M	12.25M	1.68M
Pretax Income+	-119.83M	-124.83M	-1.84B	-2.12B	-892.94M	-547.51M	-313.6M
Pretax Margin %	-221.16%	-162.85%	-585.69%	-444.08%	-355.11%	-241.15%	-184.3%
Income Tax+	22K	1.89M	-1.48M	-15.03M	-71K	-479K	-837K
Effective Tax Rate %	99.58%	101.42%	99.56%	99.22%	99.99%	99.91%	99.73%
Net Income+	-119.33M	-126.61M	-1.83B	-2.1B	-892.87M	-547.03M	-312.76M
Net Margin %	-220.23%	-165.16%	-583.12%	-440.63%	-355.08%	-240.94%	-183.81%
Net Income Growth %	-	-6.1%	-1345.43%	-15.02%	57.58%	38.73%	42.83%
Net Income (Continuing)	-119.86M	-126.72M	-1.84B	-2.11B	-892.87M	-547.03M	-312.76M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	8.79M	8.68M	62.01M	0	0	0	0
EPS (Diluted)+	-4.15	-4.00	-55.53	-50.20	-18.40	-10.54	-5.64
EPS Growth %	-	3.61%	-1288.25%	9.6%	63.35%	42.72%	46.49%
EPS (Basic)	-4.15	-3.97	-53.83	-50.15	-18.37	-10.54	-5.64
Diluted Shares Outstanding	28.73M	31.87M	34.01M	42M	48.61M	51.89M	55.46M
Basic Shares Outstanding	28.73M	31.65M	32.95M	41.93M	48.53M	51.89M	55.46M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	511.93M	426.54M	1.72B	1.45B	1B	602.74M	471.84M
Cash & Short-Term Investments	495.29M	380.8M	1.55B	1.32B	944.07M	561.57M	422.62M
Cash Only	495.29M	380.8M	1.55B	1.32B	944.07M	561.57M	167.2M
Short-Term Investments	0	0	0	0	0	0	255.42M
Accounts Receivable	7.68M	21.91M	149.9M	84.03M	17.9M	22.44M	24.03M
Days Sales Outstanding	51.72	104.3	174.34	64.2	25.98	36.08	51.54
Inventory	0	9.27M	3.36M	4.36M	46K	0	0
Days Inventory Outstanding	-	216.79	9.46	7.8	0.31	-	-
Other Current Assets	6.41M	3.71M	698K	8.71M	18.99M	18.73M	25.19M
Total Non-Current Assets+	185.39M	248.61M	347.94M	1.09B	663.59M	774.71M	647.86M
Property, Plant & Equipment	63.13M	121.44M	145.77M	718.79M	394.99M	598.15M	528.7M
Fixed Asset Turnover	0.86x	0.63x	2.15x	0.66x	0.64x	0.38x	0.32x
Goodwill	1.86M	1.86M	21.31M	60.21M	49.24M	0	0
Intangible Assets	3.84M	3.29M	21.64M	111.04M	82.74M	72.51M	56.92M
Long-Term Investments	107.25M	103.12M	115.23M	111.79M	77.91M	48.7M	15.07M
Other Non-Current Assets	9.31M	18.9M	43.99M	87.41M	58.71M	55.34M	47.17M
Total Assets+	697.32M	675.15M	2.07B	2.54B	1.67B	1.38B	1.12B
Asset Turnover	0.08x	0.11x	0.15x	0.19x	0.15x	0.16x	0.15x
Asset Growth %	-	-3.18%	206.74%	22.61%	-34.42%	-17.29%	-18.71%
Total Current Liabilities+	40.07M	73.22M	134.76M	172.96M	163.86M	107.27M	95.97M
Accounts Payable	2.44M	13.89M	8.19M	10.45M	9.32M	14.17M	10.57M
Days Payables Outstanding	-	324.83	23.05	18.68	63.01	134.16	122.35
Short-Term Debt	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	33.24M	47.82M	48.49M	30.6M	18.95M
Other Current Liabilities	23.44M	41.12M	40.31M	52.51M	54.38M	26.62M	77.02M
Current Ratio	12.77x	5.83x	12.79x	8.38x	6.11x	5.62x	4.92x
Quick Ratio	12.77x	5.70x	12.76x	8.36x	6.11x	5.62x	4.92x
Cash Conversion Cycle	-	-3.74	160.75	53.32	-36.72	-	-
Total Non-Current Liabilities+	155.39M	131.88M	368.85M	630.08M	404.33M	554.13M	515.14M
Long-Term Debt	0	0	0	0	0	0	417.08M
Capital Lease Obligations	16.77M	16.52M	22.28M	413.26M	221.84M	438.77M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	138.62M	115.36M	190.58M	42.06M	24.43M	16.58M	98.06M
Total Liabilities	195.47M	205.1M	503.61M	803.04M	568.19M	661.39M	611.11M
Total Debt+	17.36M	17M	23.03M	442.59M	239.31M	467.73M	417.08M
Net Debt	-477.92M	-363.8M	-1.53B	-873.2M	-704.76M	-93.84M	249.88M
Debt / Equity	0.03x	0.04x	0.01x	0.25x	0.22x	0.65x	0.82x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-29.57x	-57.45x	-770.53x	-20839.17x	-9294.69x	-5954.86x	-
Total Equity+	501.85M	470.05M	1.57B	1.74B	1.1B	716.06M	508.59M
Equity Growth %	-	-6.34%	233.45%	10.78%	-36.81%	-34.73%	-28.97%
Book Value per Share	17.47	14.75	46.09	41.34	22.57	13.80	9.17
Total Shareholders' Equity	493.06M	461.38M	1.51B	1.74B	1.1B	716.06M	508.59M
Common Stock	79K	129K	161K	190K	5K	5K	6K
Retained Earnings	-341.27M	-467.88M	-2.3B	-4.4B	-5.29B	-5.84B	-6.15B
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	-1.72M	-2.63M	1.48M	-1.81M	1.85M
Minority Interest	8.79M	8.68M	62.01M	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-44.66M	-135.83M	-253.82M	-252.2M	-295.5M	-319.58M	-171.06M
Operating CF Margin %	-82.43%	-177.19%	-80.88%	-52.79%	-117.52%	-140.76%	-100.53%
Operating CF Growth %	-	-204.12%	-86.86%	0.64%	-17.17%	-8.15%	46.47%
Net Income	-119.86M	-126.72M	-1.84B	-2.11B	-892.87M	-547.03M	-312.76M
Depreciation & Amortization	10.76M	13.86M	29.08M	42.55M	71.55M	63.02M	58.99M
Stock-Based Compensation	771K	476K	1.61B	1.93B	229.88M	112.34M	81.55M
Deferred Taxes	54.73M	0	30.21M	-14.61M	-801K	-936K	-1.36M
Other Non-Cash Items	-1.64M	3.07M	-20.95M	-67.4M	266.89M	142.69M	2.53M
Working Capital Changes	10.58M	-26.52M	-61.54M	-37.01M	29.84M	-89.67M	0
Change in Receivables	-1.84M	-14.23M	-114.09M	55.02M	50.07M	-4.72M	-1.47M
Change in Inventory	-2.22M	-2.74M	-626K	164K	0	0	0
Change in Payables	664K	7.02M	-2.25M	-10.84M	-1.18M	4.77M	-2.99M
Cash from Investing+	-74.6M	-67.12M	-73.26M	-67.39M	-80.69M	-62.24M	-240.29M
Capital Expenditures	-22.22M	-57.82M	-56.52M	-52.27M	-40.8M	-62.54M	-7.67M
CapEx % of Revenue	41.01%	75.43%	18.01%	10.94%	16.23%	27.55%	4.5%
Acquisitions	0	0	-12.04M	26.65M	-38.55M	-5.4M	0
Investments	-	-	-	-	-	-	-
Other Investing	-2.25M	-9.3M	304K	-38.08M	-1.34M	1.19M	624K
Cash from Financing+	410.38M	90.32M	1.53B	95.34M	-3.22M	-1.74M	0
Debt Issued (Net)	198.6M	-748K	-1.12M	-1.24M	-1.29M	-897K	0
Equity Issued (Net)	1000K	1000K	-1000K	1000K	-487K	80K	0
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-408K	0	-25M	0	-23K	0	0
Other Financing	7K	26K	1.56B	-2.73M	-1.43M	-922K	0
Net Change in Cash	291.12M	-112.63M	1.21B	-223.35M	-380M	-383.84M	0
Free Cash Flow+	-66.88M	-193.65M	-310.34M	-304.47M	-336.3M	-382.13M	-178.72M
FCF Margin %	-123.44%	-252.62%	-98.89%	-63.74%	-133.74%	-168.31%	-105.04%
FCF Growth %	-	-189.54%	-60.26%	1.89%	-10.45%	-13.63%	53.23%
FCF per Share	-2.33	-6.08	-9.13	-7.25	-6.92	-7.36	-3.22
FCF Conversion (FCF/Net Income)	0.37x	1.07x	0.14x	0.12x	0.33x	0.58x	0.55x
Interest Paid	2.35M	2.57M	2.37M	92K	83K	32K	0
Taxes Paid	31K	0	61K	0	670K	894K	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-23.78%	-26.05%	-179.64%	-127.43%	-63.02%	-60.34%	-51.08%
Return on Invested Capital (ROIC)	-224.39%	-157.88%	-1870.12%	-366.74%	-103.28%	-82.75%	-34.25%
Gross Margin	100%	79.64%	58.68%	57.25%	78.52%	83.02%	81.48%
Net Margin	-220.23%	-165.16%	-583.12%	-440.63%	-355.08%	-240.94%	-183.81%
Debt / Equity	0.03x	0.04x	0.01x	0.25x	0.22x	0.65x	0.82x
Interest Coverage	-29.57x	-57.45x	-770.53x	-20839.17x	-9294.69x	-5954.86x	-
FCF Conversion	0.37x	1.07x	0.14x	0.12x	0.33x	0.58x	0.55x
Revenue Growth	-	41.48%	309.4%	52.21%	-47.36%	-9.71%	-25.06%

US Stock Screener

...

Ginkgo Bioworks Holdings, Inc. (DNA) 10-Year Financial Performance & Capital Metrics

DNA •

HealthcareBiotechnologyDrug Discovery and Antibody Platforms

Revenue $170M -25.1%
EBITDA -$315M +36.5%
Net Income -$313M +42.8%
EPS (Diluted) -5.64 +46.5%
Gross Margin 81.48% -1.9%
EBITDA Margin -185.29% +15.3%
Operating Margin -185.29% +24.8%
Net Margin -183.81% +23.7%
ROE -51.08% +15.3%
ROIC -34.25% +58.6%
Debt/Equity 0.82 +25.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 17.3%
✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y17.29%

3Y-29.11%

TTM-25.06%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM42.83%

EPS CAGR

10Y-

5Y-

3Y-

TTM47.1%

ROCE

10Y Avg-56%

5Y Avg-71.87%

3Y Avg-37.53%

Latest-27.49%

Peer Comparison

Drug Discovery and Antibody Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
REGNRegeneron Pharmaceuticals, Inc.	107.56B	781.67	18.84	0.99%	31.41%	14.41%	3.79%	0.09
CTMXCytomX Therapeutics, Inc.	430.14M	5.37	14.13	36.45%	24.66%	26.09%
PRTCPureTech Health plc	405.3M	16.77	8.39	44.98%	-495.91%	-8.53%		0.05
DNAGinkgo Bioworks Holdings, Inc.	327.53M	6.75	-1.20	-25.06%	-183.81%	-61.5%		0.82
BCYCBicycle Therapeutics plc	111.38M	5.73	-1.98	30.76%	-8.85%	-40.53%		0.01
CCCCC4 Therapeutics, Inc.	261.67M	2.70	-2.13	-100%		-40.92%		0.23
MOLNMolecular Partners AG	187.84M	5.02	-2.43	-29.38%	-10.87%	-63.06%		0.02
RXRXRecursion Pharmaceuticals, Inc.	1.94B	3.67	-2.55	26.92%	-8.65%	-57.01%		0.07

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	54.18M	76.66M	313.84M	477.71M	251.46M	227.04M	170.16M
Revenue Growth %	-	41.48%	309.4%	52.21%	-47.36%	-9.71%	-25.06%
Cost of Goods Sold+	0	15.61M	129.69M	204.22M	54.01M	38.55M	31.52M
COGS % of Revenue	-	20.36%	41.32%	42.75%	21.48%	16.98%	18.52%
Gross Profit+	54.18M	61.05M	184.15M	273.49M	197.45M	188.49M	138.63M
Gross Margin %	100%	79.64%	58.68%	57.25%	78.52%	83.02%	81.48%
Gross Profit Growth %	-	12.66%	201.65%	48.52%	-27.8%	-4.54%	-26.45%
Operating Expenses+	125.78M	198.07M	2.01B	2.48B	1.06B	748.25M	453.91M
OpEx % of Revenue	232.14%	258.39%	641.29%	519.66%	422.28%	329.56%	266.76%
Selling, General & Admin	29.48M	38.31M	862.95M	1.43B	385.02M	246.16M	183.29M
SG&A % of Revenue	54.41%	49.97%	274.97%	299.31%	153.12%	108.42%	107.72%
Research & Development	96.3M	159.77M	1.15B	1.05B	580.62M	424.06M	243.77M
R&D % of Revenue	177.73%	208.42%	366.32%	220.35%	230.9%	186.78%	143.27%
Other Operating Expenses	0	0	0	0	96.21M	78.03M	26.85M
Operating Income+	-71.6M	-137.03M	-1.83B	-2.21B	-864.41M	-559.76M	-315.28M
Operating Margin %	-132.14%	-178.75%	-582.62%	-462.41%	-343.76%	-246.54%	-185.29%
Operating Income Growth %	-	-91.38%	-1234.38%	-20.81%	60.87%	35.24%	43.68%
EBITDA+	-60.84M	-123.16M	-1.8B	-2.15B	-792.85M	-496.74M	-315.28M
EBITDA Margin %	-112.29%	-160.67%	-573.35%	-449.51%	-315.31%	-218.79%	-185.29%
EBITDA Growth %	-	-102.43%	-1360.98%	-19.34%	63.08%	37.35%	36.53%
D&A (Non-Cash Add-back)	10.76M	13.86M	29.08M	61.63M	71.55M	63.02M	0
EBIT	-117.41M	-122.45M	-1.84B	-2.12B	-892.85M	-547.41M	0
Net Interest Income+	3.33M	197K	-1.54M	20.16M	57.12M	38.52M	0
Interest Income	5.76M	2.58M	837K	20.26M	57.22M	38.61M	22.62M
Interest Expense	2.42M	2.38M	2.37M	106K	93K	94K	0
Other Income/Expense	-48.24M	12.19M	-9.65M	87.55M	-28.53M	12.25M	1.68M
Pretax Income+	-119.83M	-124.83M	-1.84B	-2.12B	-892.94M	-547.51M	-313.6M
Pretax Margin %	-221.16%	-162.85%	-585.69%	-444.08%	-355.11%	-241.15%	-184.3%
Income Tax+	22K	1.89M	-1.48M	-15.03M	-71K	-479K	-837K
Effective Tax Rate %	99.58%	101.42%	99.56%	99.22%	99.99%	99.91%	99.73%
Net Income+	-119.33M	-126.61M	-1.83B	-2.1B	-892.87M	-547.03M	-312.76M
Net Margin %	-220.23%	-165.16%	-583.12%	-440.63%	-355.08%	-240.94%	-183.81%
Net Income Growth %	-	-6.1%	-1345.43%	-15.02%	57.58%	38.73%	42.83%
Net Income (Continuing)	-119.86M	-126.72M	-1.84B	-2.11B	-892.87M	-547.03M	-312.76M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	8.79M	8.68M	62.01M	0	0	0	0
EPS (Diluted)+	-4.15	-4.00	-55.53	-50.20	-18.40	-10.54	-5.64
EPS Growth %	-	3.61%	-1288.25%	9.6%	63.35%	42.72%	46.49%
EPS (Basic)	-4.15	-3.97	-53.83	-50.15	-18.37	-10.54	-5.64
Diluted Shares Outstanding	28.73M	31.87M	34.01M	42M	48.61M	51.89M	55.46M
Basic Shares Outstanding	28.73M	31.65M	32.95M	41.93M	48.53M	51.89M	55.46M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	511.93M	426.54M	1.72B	1.45B	1B	602.74M	471.84M
Cash & Short-Term Investments	495.29M	380.8M	1.55B	1.32B	944.07M	561.57M	422.62M
Cash Only	495.29M	380.8M	1.55B	1.32B	944.07M	561.57M	167.2M
Short-Term Investments	0	0	0	0	0	0	255.42M
Accounts Receivable	7.68M	21.91M	149.9M	84.03M	17.9M	22.44M	24.03M
Days Sales Outstanding	51.72	104.3	174.34	64.2	25.98	36.08	51.54
Inventory	0	9.27M	3.36M	4.36M	46K	0	0
Days Inventory Outstanding	-	216.79	9.46	7.8	0.31	-	-
Other Current Assets	6.41M	3.71M	698K	8.71M	18.99M	18.73M	25.19M
Total Non-Current Assets+	185.39M	248.61M	347.94M	1.09B	663.59M	774.71M	647.86M
Property, Plant & Equipment	63.13M	121.44M	145.77M	718.79M	394.99M	598.15M	528.7M
Fixed Asset Turnover	0.86x	0.63x	2.15x	0.66x	0.64x	0.38x	0.32x
Goodwill	1.86M	1.86M	21.31M	60.21M	49.24M	0	0
Intangible Assets	3.84M	3.29M	21.64M	111.04M	82.74M	72.51M	56.92M
Long-Term Investments	107.25M	103.12M	115.23M	111.79M	77.91M	48.7M	15.07M
Other Non-Current Assets	9.31M	18.9M	43.99M	87.41M	58.71M	55.34M	47.17M
Total Assets+	697.32M	675.15M	2.07B	2.54B	1.67B	1.38B	1.12B
Asset Turnover	0.08x	0.11x	0.15x	0.19x	0.15x	0.16x	0.15x
Asset Growth %	-	-3.18%	206.74%	22.61%	-34.42%	-17.29%	-18.71%
Total Current Liabilities+	40.07M	73.22M	134.76M	172.96M	163.86M	107.27M	95.97M
Accounts Payable	2.44M	13.89M	8.19M	10.45M	9.32M	14.17M	10.57M
Days Payables Outstanding	-	324.83	23.05	18.68	63.01	134.16	122.35
Short-Term Debt	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	33.24M	47.82M	48.49M	30.6M	18.95M
Other Current Liabilities	23.44M	41.12M	40.31M	52.51M	54.38M	26.62M	77.02M
Current Ratio	12.77x	5.83x	12.79x	8.38x	6.11x	5.62x	4.92x
Quick Ratio	12.77x	5.70x	12.76x	8.36x	6.11x	5.62x	4.92x
Cash Conversion Cycle	-	-3.74	160.75	53.32	-36.72	-	-
Total Non-Current Liabilities+	155.39M	131.88M	368.85M	630.08M	404.33M	554.13M	515.14M
Long-Term Debt	0	0	0	0	0	0	417.08M
Capital Lease Obligations	16.77M	16.52M	22.28M	413.26M	221.84M	438.77M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	138.62M	115.36M	190.58M	42.06M	24.43M	16.58M	98.06M
Total Liabilities	195.47M	205.1M	503.61M	803.04M	568.19M	661.39M	611.11M
Total Debt+	17.36M	17M	23.03M	442.59M	239.31M	467.73M	417.08M
Net Debt	-477.92M	-363.8M	-1.53B	-873.2M	-704.76M	-93.84M	249.88M
Debt / Equity	0.03x	0.04x	0.01x	0.25x	0.22x	0.65x	0.82x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-29.57x	-57.45x	-770.53x	-20839.17x	-9294.69x	-5954.86x	-
Total Equity+	501.85M	470.05M	1.57B	1.74B	1.1B	716.06M	508.59M
Equity Growth %	-	-6.34%	233.45%	10.78%	-36.81%	-34.73%	-28.97%
Book Value per Share	17.47	14.75	46.09	41.34	22.57	13.80	9.17
Total Shareholders' Equity	493.06M	461.38M	1.51B	1.74B	1.1B	716.06M	508.59M
Common Stock	79K	129K	161K	190K	5K	5K	6K
Retained Earnings	-341.27M	-467.88M	-2.3B	-4.4B	-5.29B	-5.84B	-6.15B
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	-1.72M	-2.63M	1.48M	-1.81M	1.85M
Minority Interest	8.79M	8.68M	62.01M	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-44.66M	-135.83M	-253.82M	-252.2M	-295.5M	-319.58M	-171.06M
Operating CF Margin %	-82.43%	-177.19%	-80.88%	-52.79%	-117.52%	-140.76%	-100.53%
Operating CF Growth %	-	-204.12%	-86.86%	0.64%	-17.17%	-8.15%	46.47%
Net Income	-119.86M	-126.72M	-1.84B	-2.11B	-892.87M	-547.03M	-312.76M
Depreciation & Amortization	10.76M	13.86M	29.08M	42.55M	71.55M	63.02M	58.99M
Stock-Based Compensation	771K	476K	1.61B	1.93B	229.88M	112.34M	81.55M
Deferred Taxes	54.73M	0	30.21M	-14.61M	-801K	-936K	-1.36M
Other Non-Cash Items	-1.64M	3.07M	-20.95M	-67.4M	266.89M	142.69M	2.53M
Working Capital Changes	10.58M	-26.52M	-61.54M	-37.01M	29.84M	-89.67M	0
Change in Receivables	-1.84M	-14.23M	-114.09M	55.02M	50.07M	-4.72M	-1.47M
Change in Inventory	-2.22M	-2.74M	-626K	164K	0	0	0
Change in Payables	664K	7.02M	-2.25M	-10.84M	-1.18M	4.77M	-2.99M
Cash from Investing+	-74.6M	-67.12M	-73.26M	-67.39M	-80.69M	-62.24M	-240.29M
Capital Expenditures	-22.22M	-57.82M	-56.52M	-52.27M	-40.8M	-62.54M	-7.67M
CapEx % of Revenue	41.01%	75.43%	18.01%	10.94%	16.23%	27.55%	4.5%
Acquisitions	0	0	-12.04M	26.65M	-38.55M	-5.4M	0
Investments	-	-	-	-	-	-	-
Other Investing	-2.25M	-9.3M	304K	-38.08M	-1.34M	1.19M	624K
Cash from Financing+	410.38M	90.32M	1.53B	95.34M	-3.22M	-1.74M	0
Debt Issued (Net)	198.6M	-748K	-1.12M	-1.24M	-1.29M	-897K	0
Equity Issued (Net)	1000K	1000K	-1000K	1000K	-487K	80K	0
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-408K	0	-25M	0	-23K	0	0
Other Financing	7K	26K	1.56B	-2.73M	-1.43M	-922K	0
Net Change in Cash	291.12M	-112.63M	1.21B	-223.35M	-380M	-383.84M	0
Free Cash Flow+	-66.88M	-193.65M	-310.34M	-304.47M	-336.3M	-382.13M	-178.72M
FCF Margin %	-123.44%	-252.62%	-98.89%	-63.74%	-133.74%	-168.31%	-105.04%
FCF Growth %	-	-189.54%	-60.26%	1.89%	-10.45%	-13.63%	53.23%
FCF per Share	-2.33	-6.08	-9.13	-7.25	-6.92	-7.36	-3.22
FCF Conversion (FCF/Net Income)	0.37x	1.07x	0.14x	0.12x	0.33x	0.58x	0.55x
Interest Paid	2.35M	2.57M	2.37M	92K	83K	32K	0
Taxes Paid	31K	0	61K	0	670K	894K	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-23.78%	-26.05%	-179.64%	-127.43%	-63.02%	-60.34%	-51.08%
Return on Invested Capital (ROIC)	-224.39%	-157.88%	-1870.12%	-366.74%	-103.28%	-82.75%	-34.25%
Gross Margin	100%	79.64%	58.68%	57.25%	78.52%	83.02%	81.48%
Net Margin	-220.23%	-165.16%	-583.12%	-440.63%	-355.08%	-240.94%	-183.81%
Debt / Equity	0.03x	0.04x	0.01x	0.25x	0.22x	0.65x	0.82x
Interest Coverage	-29.57x	-57.45x	-770.53x	-20839.17x	-9294.69x	-5954.86x	-
FCF Conversion	0.37x	1.07x	0.14x	0.12x	0.33x	0.58x	0.55x
Revenue Growth	-	41.48%	309.4%	52.21%	-47.36%	-9.71%	-25.06%

Ginkgo Bioworks Holdings, Inc. (DNA) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare DNA vs Peers

vs REGN

vs CNTA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Ginkgo Bioworks Holdings, Inc. (DNA) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare DNA vs Peers

vs REGN

vs CNTA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios